Literature DB >> 7833382

Cell proliferation kinetics of normal and tumour tissue in vitro: quiescent reproductive cells and the cycling reproductive fraction.

F L Baker1, L J Sanger, R W Rodgers, K Jabboury, O R Mangini.   

Abstract

Current methods for measuring the cell kinetics of human tumours are made and interpreted within the context of a simplistic two compartment model for cell proliferation, consisting of cells that are cycling and those that are not. It is now recognized that the non-cycling compartment of many tumours is heterogeneous, composed of non-reproductive end-stage cells and reproductive cells that are dormant/quiescent. We have developed an in vitro analysis that distinguishes for the first time quiescent reproductive cells from non-reproductive end-stage cells and have integrated this analysis with monolayer clonogenic and suicide assays to simultaneously quantitate the duration of the cell cycle and reproductive cells that are: cycling, quiescent, clonogenic, and non-reproductive end-stage cells. We have defined a new parameter, the Cycling Reproductive Fraction (CRF), which is the cycling cell population referenced specifically to the reproductive cell population. Measurements of CRF from 72 tumour biopsies and from 5 normal foreskins showed that CRF approached 100% in some tumours; however, CRF showed near normal values (< 1%) in others suggesting that cell cycle control may be maintained in some tumours. Because of CRF's improved specificity, we believe that CRF may enhance classification, prognostication, and the optimization and prediction of response to chemotherapy.

Entities:  

Mesh:

Year:  1995        PMID: 7833382     DOI: 10.1111/j.1365-2184.1995.tb00035.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  8 in total

1.  Negative clonal selection in tumor evolution.

Authors:  Robert A Beckman; Lawrence A Loeb
Journal:  Genetics       Date:  2005-09-02       Impact factor: 4.562

2.  Efficiency of carcinogenesis with and without a mutator mutation.

Authors:  Robert A Beckman; Lawrence A Loeb
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

3.  Reply: Is There Any Genetic Instability in Human Cancer?

Authors:  Edward J Fox; Robert A Beckman; Lawrence A Loeb
Journal:  DNA Repair (Amst)       Date:  2010-06-29

4.  Fibroblast growth factor 2 inhibits myofibroblastic activation of valvular interstitial cells.

Authors:  Marcus Ground; Steve Waqanivavalagi; Young-Eun Park; Karen Callon; Robert Walker; Paget Milsom; Jillian Cornish
Journal:  PLoS One       Date:  2022-06-17       Impact factor: 3.752

Review 5.  Mathematical models of breast and ovarian cancers.

Authors:  Dana-Adriana Botesteanu; Stanley Lipkowitz; Jung-Min Lee; Doron Levy
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2016-06-03

Review 6.  Measuring proliferation in breast cancer: practicalities and applications.

Authors:  Mark J Beresford; George D Wilson; Andreas Makris
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

7.  Long range personalized cancer treatment strategies incorporating evolutionary dynamics.

Authors:  Chen-Hsiang Yeang; Robert A Beckman
Journal:  Biol Direct       Date:  2016-10-22       Impact factor: 4.540

8.  A signature-based method for indexing cell cycle phase distribution from microarray profiles.

Authors:  Hideaki Mizuno; Yoshito Nakanishi; Nobuya Ishii; Akinori Sarai; Kunio Kitada
Journal:  BMC Genomics       Date:  2009-03-30       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.